Injectable Neurostimulation System
Obstructive Sleep Apnea (OSA)
Key Facts
About Invicta Medical
Restera is pioneering a disruptive, minimally invasive neurostimulation therapy for Obstructive Sleep Apnea (OSA), a condition affecting an estimated one billion people globally. The company's core innovation is a miniature implant placed via needle injection under ultrasound guidance, targeting novel neural structures like the hypoglossal nerve and ansa cervicalis to open the airway. With a strong clinical and scientific advisory board, over 50 patents, and multiple successful proof-of-concept human studies, Restera is advancing a solution aimed at overcoming the severe compliance issues plaguing the dominant CPAP market. The company is positioned to address a massive, underserved market with significant economic burden.
View full company profileTherapeutic Areas
Other Obstructive Sleep Apnea (OSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-110 | SciSparc | Preclinical |
| DeltaWave CPAP Nasal Pillow System | Remsleep | Commercial |
| AD109 | Apnimed | Phase 3 |
| Sleep Apnea Biomarker Services | The Siesta Group | Service Offering |
| IHL-42X | Incannex Healthcare | Phase 2/3 |